NCT06568172 2026-03-19
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
University Health Network, Toronto
Eastern Cooperative Oncology Group
Jonsson Comprehensive Cancer Center
Umeå University